Acute effects of the sodium glucose transporter (SGLT) -2 inhibitors,Dapagliflozin, on Hemorheology,Leukocyte Activation and Oxidative Stress in type 2 diabetes.
- Conditions
- Type2 Diabetes
- Registration Number
- JPRN-UMIN000024821
- Lead Sponsor
- Dokkyo Medical University Nikko Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Not provided
(a) Patients with type 1 diabetes mellitus (b) Patients with a medical history of hypersensitivity to any of the ingredients of dapagliflozin (c) Patients with severe ketosis or diabetic coma or pre-coma (d) Patients who have severe infection, are pre- or postoperative, or have sustained serious trauma (e) Patients with severe impaired liver function (f) Patients who are susceptible to dehydration (g) Patients with urinary tract infection or genital infection (h) Patients with a history of cerebrovascular disease within the last 3 months (i) Women who are pregnant or breastfeeding or who may be pregnant (j) Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 mL (k) Patients on warfarin or a novel oral anticoagulant (NOAC) (dabigatran, rivaroxaban, edoxaban, or apixaban) (l) Patients otherwise deemed to be unsuitable for the clinical study by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Whole blood transit time and the difference from baseline at 48h after Dapagliflozin treatment, as assessed using microchannel array flow analyzer equipped with BK7-7-7D chip.nowo
- Secondary Outcome Measures
Name Time Method a)Leukocyte activation (adhesive leukocyte count as determined using the MC-FAN with DKAMCM1-60-7-4.5Denrollment b)Hs-CRP C)Oxidative stress as determined by the d-ROMs test d)Complete blood count